Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + gemcitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- IDEC
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
R-GemOx is a combination chemotherapy regimen consisting of rituximab (a CD20-targeting monoclonal antibody), gemcitabine (an antimetabolite), and oxaliplatin (a platinum analog). This regimen is primarily used for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in patients who are ineligible for autologous stem cell transplantation. The treatment is typically administered in 14-day cycles, with rituximab, gemcitabine, and oxaliplatin all given on day 1 of each cycle.
- Brand names
- R-GemOx
- Other names
- R-GemOXGemOx + Rituximab
02
Targets
Beyond the preview
Go deeper on rituximab + gemcitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + gemcitabine + oxaliplatin.